A Clinical Comparison of Pycnogenol, Antistax, and Stocking in Chronic Venous Insufficiency

Gianni Belcaro

doi:10.1055/s-0035-1556060

International Journal of Angiology, Inhaltsverzeichnis

Int J Angiol 2015; 24(04): 268-274
DOI: 10.1055/s-0035-1556060

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Clinical Comparison of Pycnogenol, Antistax, and Stocking in Chronic Venous Insufficiency

Gianni Belcaro

¹Irvine3 Labs, Biomedical Sciences, Chieti-Pescara University, Italy

› Institutsangaben

Abstract

This 8-week registry study was a comparative evaluation of Pycnogenol (French Maritime Pine Bark extract; Horphag Research, Geneva) and Antistax (grape leaf extract [GLE, Boehringer Ingelheim, Germany]) in controlling symptoms of chronic venous insufficiency (CVI). “Standard management” for CVI is compression; a group of comparable subjects was monitored to evaluate the effects of stockings. The registry included 183 patients (166 completing). Supplementation with Antistax (two tablets of 360 mg/d) or Pycnogenol (100 mg/d) was used. The groups were comparable for age, symptoms, venous incompetence, and microcirculation (with increased capillary filtration and skin flux) at inclusion. At 8 weeks, the rate of swelling (p < 0.05) and skin flux decreased toward normal values; changes were more important with Pycnogenol (p < 0.05). Transcutaneous Po ₂ was increased more with Pycnogenol (p < 0.05). Ankle circumference was decreased more (p < 0.05) with Pycnogenol. An analog scale quantified symptoms. At 8 weeks, pain and edema were decreased with Pycnogenol and elastic compression (p < 0.05) with prevalence for Pycnogenol (p < 0.05). Edema with Pycnogenol was decreased by 40%. Induration was reduced only in the Pycnogenol group (p < 0.05) with minimal variations in the other groups. Tolerability and compliance were optimal. Elastic compression was correctly used by 80% of the patients indicating that it may be more difficult to use, particularly in warmer days. Costs for Pycnogenol were lower (96; 3.3 Euros) in comparison with the other groups (132;1.4 Euros for GLE and 149; 2.2 Euros for compression).

Keywords

edema - venous insufficiency - supplements - Pycnogenol - Antistax - Stockings

Volltext

Referenzen

References
1 Nicolaides AN ; Cardiovascular Disease Educational and Research Trust; European Society of Vascular Surgery; The International Angiology Scientific Activity Congress Organization; International Union of Angiology; Union Internationale de Phlebologie at the Abbaye des Vaux de Cernay. Investigation of chronic venous insufficiency: A consensus statement (France, March 5-9, 1997). Circulation 2000; 102 (20) E126-E163
2 Christopoulos D, Tachtsi M, Pitoulias G, Belcaro G, Papadimitriou D. Hemodynamic follow-up of iliofemoral venous thrombosis. Int Angiol 2009; 28 (5) 394-399
3 Porter RS, Kaplan JL. The Merck Manual; 12th ed. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; 2011
4 Gulati OP. Pycnogenol® in chronic venous insufficiency and related venous disorders. Phytother Res 2014; 28 (3) 348-362
5 Esperester A, Schütt T, Ottillinger B. Drugs in chronic venous insufficiency—the challenge of demonstrating clinical efficacy [in German]. Med Monatsschr Pharm 2013; 36 (2) 44-51
6 Rabe E, Stücker M, Esperester A, Schäfer E, Ottillinger B. Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency—results of a double-blind placebo-controlled study. Eur J Vasc Endovasc Surg 2011; 41 (4) 540-547
7 Butcher M. A review of evidence on red vine leaf extract in the prevention and management of venous disease. J Wound Care 2006; 15 (9) 393-396
8 Monsieur R, Van Snick G. Efficacy of the red vine leaf extract AS 195 in Chronic Venous Insufficiency [in French]. Praxis (Bern 1994) 2006; 95 (6) 187-190
9 Rabe E, Pannier F, Larenz B. Red vine leaf extract (AX 195) for chronic venous insufficiency [in German]. Med Monatsschr Pharm 2005; 28 (2) 55-59
10 Belcaro G, Nicolaides AN. The Venous Clinic. London: Imperial College Press; 2006
11 Belcaro G, Nicolaides AN, Veller M. A Manual of Venous Disorders. London: Saunders; 2001
12 Belcaro G, Nicolaides AN. Noninvasive Investigations in Vascular Disease. London: Imperial College Press; 2007
13 Belcaro G, Hoffman U, Bollinger A, Nicolaides AN. Laser Doppler. Med_Orion, London 1999
14 Belcaro G. Laser Doppler. PhD Thesis, University College London 1997
15 Belcaro G, Cesarone MR, de Sanctis MT , et al. Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency. Int J Microcirc Clin Exp 1995; 15 (Suppl. 01) 45-49
16 Passman MA, McLafferty RB, Lentz MF , et al. Validation of Venous Clinical Severity Score (VCSS) with other venous severity assessment tools from the American Venous Forum, National Venous Screening Program. J Vasc Surg 2011; 54 (6, Suppl): 2S-9S
17 Kakkos SK, Rivera MA, Matsagas MI , et al. Validation of the new venous severity scoring system in varicose vein surgery. J Vasc Surg 2003; 38 (2) 224-228
18 Nicolaides AN, Belcaro G, Chan P. Chronic deep venous insufficiency. In: Ascer E, Hollier L, Strandness DE, Towe JB, eds. Haimovici's Vascular Surgery. Cambridge, CA: Blackwell Sciences; 1996
19 Belcaro G, Cornelli U, Ledda A, Hosoi M. Assessment of nutraceuticals and food supplements. Panminerva Med 2011; 53 (3) (Suppl. 01) I-II
20 Belcaro G, Nicolaides AN. Natural drugs in vascular medicine: new observations. J Cardiovasc Pharmacol Ther 2002; 7 (Suppl. 01) S1
21 Belcaro G, Nicolaides AN. A new role for natural drugs in cardiovascular medicine. Angiology 2001; 52 (Suppl. 02) S1
22 Singh R, Wang O. Clinical trials in “emerging markets”: regulatory considerations and other factors. Contemp Clin Trials 2013; 36 (2) 711-718
23 Belcaro G, Cornelli U, Dugall M, Luzzi R, Hosoi M, Ledda A , et al. Panel 2013 Supplements and green drugs studies; New rules 2013. London and Annecy Panel. Angiology. online. blogspot.com
24 Gabriel RA, Gimlich R, Ehrenfeld JM, Urman RD. Operating room metrics score card-creating a prototype for individualized feedback. J Med Syst 2014; 38 (11) 144
25 Center for Individualized Medicine Available at: http://mayoresearch.mayo.edu/center-for-individualized-medicine/personalized-medicine.asp . Accessed March 2015
26 Belcaro G, Dugall M, Luzzi R, Hosoi M, Corsi M. Improvements of venous tone with pycnogenol in chronic venous insufficiency: an ex vivo study on venous segments. Int J Angiol 2014; 23 (1) 47-52
27 Errichi BM, Belcaro G, Hosoi M , et al. Prevention of post thrombotic syndrome with Pycnogenol® in a twelve month study. Panminerva Med 2011; 53 (3) (Suppl. 01) 21-27
28 Cesarone MR, Belcaro G, Rohdewald P , et al. Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: a prospective, controlled study. Phytomedicine 2010; 17 (11) 835-839
29 Cesarone MR, Belcaro G, Rohdewald P , et al. Rapid relief of signs/symptoms in chronic venous microangiopathy with pycnogenol: a prospective, controlled study. Angiology 2006; 57 (5) 569-576
30 Belcaro G, Cesarone MR, Ricci A , et al. Control of edema in hypertensive subjects treated with calcium antagonist (nifedipine) or angiotensin-converting enzyme inhibitors with Pycnogenol. Clin Appl Thromb Hemost 2006; 12 (4) 440-444
31 Cesarone MR, Belcaro G, Rohdewald P , et al. Comparison of Pycnogenol and Daflon in treating chronic venous insufficiency: a prospective, controlled study. Clin Appl Thromb Hemost 2006; 12 (2) 205-212
32 Vinciguerra G, Belcaro G, Cesarone MR , et al. Cramps and muscular pain: prevention with pycnogenol in normal subjects, venous patients, athletes, claudicants and in diabetic microangiopathy. Angiology 2006; 57 (3) 331-339
33 Belcaro G, Cesarone MR, Errichi BM , et al. Venous ulcers: microcirculatory improvement and faster healing with local use of Pycnogenol. Angiology 2005; 56 (6) 699-705